Yi-Li Chen

Yi-Li Chen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
YCYi-Li Chen
Yi-Li Chen
YCYue Cui
Yue Cui
XLXinyuan Liu
Xinyuan Liu
GLGuojian Liu
Guojian Liu
XDXingchen Dong
Xingchen Dong
MFMeiqing Feng
Meiqing Feng
Activation of the programmed cell death protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) signaling axis plays important roles in intrinsic or acquired resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies in the clinic. Therefore, therapies simultaneously targeting both HER2 and PD-1/PD-L1 signaling pathways are of great significance. Here, aiming to direct the anti-PD-L1 responses toward HER2-expressing tumor cells, we constructed a humanized bispecific IgG1 subclass antibody targeting both HER2 and PD-L1 (HER2/PD-L1; BsAb), which displayed satisfactory purity, thermostability, and serum stability. We found that BsAb showed enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro. In the late phase of peripheral blood mononuclear cell (PBMC)-humanized HER2+ tumor xenograft models, BsAb showed superior therapeutic efficacies as compared with monoclonal antibodies (mAbs) or combination treatment strategies. In cynomolgus monkeys, BsAb showed favorable pharmacokinetics and toxicity profiles when administered at a 10 mg/kg dosage. Thus, HER2/PD-L1 BsAb was demonstrated as a potentially effective option for managing HER2+ and trastuzumab-resistant tumors in the clinic. We propose that the enhanced antitumor activities of BsAb in vivo may be due to direct inhibition of HER2 signaling or activation of T cells.

16 June 2023 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
HLHua-Ying Li
Hua-Ying Li
YCYi-Li Chen
Yi-Li Chen
XDXiang-Nan Deng
Xiang-Nan Deng
HLHuan-Huan Li
Huan-Huan Li
JTJie Tan
Jie Tan
CWChunhe Wang
Chunhe Wang
Clinical application of PD-1 and PD-L1 monoclonal antibodies (mAbs) is hindered by their relatively low response rates and the occurrence of drug resistance. Co-expression of B7-H3 with PD-L1 has been found in various solid tumors, and combination therapies that target both PD-1/PD-L1 and B7-H3 pathways may provide additional therapeutic benefits. Up to today, however, no bispecific antibodies targeting both PD-1 and B7-H3 have reached the clinical development stage. In this study, we generated a stable B7-H3×PD-L1 bispecific antibody (BsAb) in IgG1-VHH format by coupling a humanized IgG1 mAb against PD-L1 with a humanized camelus variable domain of the heavy-chain of heavy-chain antibody (VHH) against human B7-H3. The BsAb exhibited favorable thermostability, efficient T cell activation, IFN-γ production, and antibody-dependent cell-mediated cytotoxicity (ADCC). In a PBMC humanized A375 xenogeneic tumor model, treatment with BsAb (10 mg/kg, i.p., twice a week for 6 weeks) showed enhanced antitumor activities compared to monotherapies and, to some degree, combination therapies. Our results suggest that targeting both PD-1 and B7-H3 with BsAbs increases their specificities to B7-H3 and PD-L1 double-positive tumors and induces a synergetic effect. We conclude that B7-H3×PD-L1 BsAb is favored over mAbs and possibly combination therapies in treating B7-H3 and PD-L1 double-positive tumors.

3 May 2022 in FEBS Open Bio
Verified
Journal Article
Open access
XDXingchen Dong
Xingchen Dong
HLHuanhuan Li
Huanhuan Li
MPMin Pei
Min Pei
JTJie Tan
Jie Tan
GCGanjun Chen
Ganjun Chen
CWChunhe Wang
Chunhe Wang
Current treatment options for diabetic neuralgia are limited and unsatisfactory. Tanezumab, a monoclonal antibody that blocks nerve growth factor (NGF) signaling, has been shown to be effective in relieving the clinical symptoms of osteoarthritis pain, chronic low back pain, cancer pain induced by bone metastasis, and diabetic neuralgia. However, the clinical development of tanezumab has been terminated due to the risk of induction of rapidly progressive osteoarthritis (RPOA), and no other NGF antibodies have been examined for their ability to treat diabetic neuralgia in either animal models or clinical trials. In this study, a humanized high‐affinity NGF monoclonal antibody (mAb), huAb45 that could neutralize the interaction between NGF and its high‐affinity receptor TrkA. In a mouse diabetic neuralgia model, it effectively relieved neuropathic pain. This study may serve as the necessary foundation for future studies of huAb45 to potentially treat diabetic neuralgia.

18 August 2022 in FEBS Open Bio
Verified
Journal Article
Open access
XLXin‐Yuan Liu
Xin‐Yuan Liu
YCYi-Li Chen
Yi-Li Chen
GLGuo‐Jian Liu
Guo‐Jian Liu
XDXiang‐Nan Deng
Xiang‐Nan Deng
YCYue Cui
Yue Cui
CWChunhe Wang
Chunhe Wang
Dinutuximab (ch14.18) was the first approved monoclonal antibody against the tumor‐associated antigen disialoganglioside GD2. Despite its success in treating neuroblastoma (NB), it triggers a significant amount of neuropathic pain in patients, possibly through complement‐dependent cytotoxicity (CDC). We hypothesized that modifying ch14.18 using antibody engineering techniques, such as humanization, affinity maturation, and Fc engineering, may enable the development of next‐generation GD2‐specific antibodies with reduced neuropathic pain and enhanced antitumor activity. In this study we developed the H3‐16 IgG1m4 antibody from ch14.18 IgG1. H3‐16 IgG1m4 exhibited enhanced binding activity to GD2 molecules and GD2‐positive cell lines as revealed by ELISA, and its cross‐binding activity to other gangliosides was not altered. The CDC activity of H3‐16 IgG1m4 was decreased, and the antibody‐dependent cellular cytotoxicity (ADCC) activity was enhanced. The pain response after H3‐16 IgG1m4 antibody administration was also reduced, as demonstrated using the von Frey test in Sprague–Dawley (SD) rats. In summary, H3‐16 IgG1m4 may have potential as a monoclonal antibody with reduced side effects.

29 September 2022 in Bio-Protocol
Verified
Journal Article
Closed access
MPMin Pei
Min Pei
LTLei Tang
Lei Tang
YWYao Wang
Yao Wang
WWWeitao Wu
Weitao Wu
CWChunhe Wang
Chunhe Wang
YCYi-Li Chen
Yi-Li Chen
An open platform for life scientists to share, find,and discuss research protocols

10 March 2026 in Protein Expression and Purification
Verified
Journal Article
Closed access
APAiling Pan
Ailing Pan
CYCaiyi Yuan
Caiyi Yuan
YWYaru Wang
Yaru Wang
CQChengcheng Qiu
Chengcheng Qiu
GLGuojian Liu
Guojian Liu
CWChunhe Wang
Chunhe Wang